1428P - Application of KM-CART (advanced cell-free and concentrated ascites reinfusion therapy) treatment to patients with cancerous ascites

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Palliative Care
Presenter Keisuke Matsusaki
Authors K. Matsusaki, K. Ohta, A. Yoshizawa, S. Goto
  • Ascites Treatment Center, Japanese CART Study Group, 1710043 - Tokyo/JP

Abstract

Purpose

The purpose of our study was to demonstrate the utility of KM-CART therapy in the care of patients with refractory ascites. We also report one colon cancer case treated with a dendritic cell vaccine that was prepared utilizing the high yield number of autologous carcinoma cells collected in KM-CART processing. Patients with refractory ascites can suffer severe bloating and/or respiratory discomfort disrupting both their activities of daily living (ADL) and terminating their anticancer therapy. We developed a novel KM-CART system for cancerous ascites using original CART system approved by the Ministry of Health, Labor and Welfare. KM-CART consists of ex vivo double filtration processing of autologous ascites fluid to prepare: (1) a protein (albumin and globulins) concentrate fraction suitable for intravenous fluid therapy back to the donor patient intravenously, and (2) a cell concentrate suitable for research for anticancer drug sensitivity and immunotherapy.

Method and results

A total of 317 cancerous ascites cases with diverse tumor origins were treated with KM-CART during 2009 to 2012. The volume of ascites extracted ranged between 2 to 15 L with an average of 5.9 L. The average KM-CART processing time was 51 minutes to produce a protein concentrate volume of 80 to 2,000 ml with a total protein concentration range of 8.0 - 21.0 g/dl. The protein concentrates were administered intravenously with an average infusion volume of 630ml. In all the cases, patients had an immediate benefit of KM-CART treatment including relief of discomfort of abdomen distension, malaise, respiratory distress and improved resumption of ADL. A total of 3.5L protein concentrates including 611g of albumin and globulin was re-infused into one 37 year old female patient with colon cancer over 3 periods of KM-CART treatment. Dendritic cell vaccine was prepared using total of 1.4x108 cancer cells which were collected from hollow fiber membrane filters.

Conclusion

KM-CART treated patients were observed to reliably respond to treatment. It is concluded that processing a large quantity of ascites fluid using the KM-CART system offers a safe and effective means to enhance refractory ascites patient care.

Disclosure

All authors have declared no conflicts of interest.